Medpace Reports Third-Quarter Revenue of $716M and EPS of $4.84
Revenue rose 8.5% year over year to $716M; net income increased 23.7% to $137.46M and diluted EPS rose 25.4% to $4.84. Growth was led by Metabolic, Oncology and CNS services.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.